A Phase 1b/2, open-label, pan-cancer study designed to evaluate the efficacy and safety of Ifinatamab Deruxtecan (I-DXd) in patients with recurrent or metastatic solid tumors.
Contact Information for Access
Status
ATTIVO
Objective of the study
To evaluate the efficacy of I-DXd in various types of cancer and to assess the safety and tolerability of I-DXd in patients with HCC.
Multiple cancer types:
Urothelial
Liver
ClinicalTrials.gov ID NCT06330064
Sponsor: Daiichi Sankyo
Medication
DS-7300a (I-DXd ADC, anti-B7-H3)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra who have received prior chemotherapy and at least one prior treatment with checkpoint inhibitors.
View the full study Back to search page